Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sarepta Therapeutics Inc    SRPT

SAREPTA THERAPEUTICS INC

(SRPT)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/17/2019 04/18/2019 04/22/2019 04/23/2019 04/24/2019 Date
118.73(c) 116.64(c) 113.79(c) 118.09(c) 118.16(c) Last
1 605 247 2 391 551 1 198 149 1 422 139 637 679 Volume
-2.35% -1.76% -2.44% +3.78% +0.06% Change
More quotes
Financials (USD)
Sales 2019 393 M
EBIT 2019 -314 M
Net income 2019 -292 M
Finance 2019 559 M
Yield 2019 -
Sales 2020 608 M
EBIT 2020 -130 M
Net income 2020 -114 M
Finance 2020 607 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 20,7x
EV / Sales2020 13,3x
Capitalization 8 700 M
More Financials
Company
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to... 
More about the company
Surperformance© ratings of Sarepta Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on SAREPTA THERAPEUTICS INC
04/19CATALENT : Paragon to Build Second GMP Mfg. Facility
AQ
04/09SAREPTA THERAPEUTICS' : Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clin..
AQ
04/09SAREPTA THERAPEUTICS : Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clini..
AQ
04/08Sarepta Therapeutics' Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Cli..
GL
04/01SAREPTA THERAPEUTICS : Announces Inducement Grants Under Nasdaq Listing Rule 563..
AQ
03/30SAREPTA THERAPEUTICS : to seek speedy approval of third DMD drug
AQ
03/29Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 56..
GL
03/29SAREPTA THERAPEUTICS : Announces Positive Expression Results from the Casimersen..
AQ
03/29SAREPTA THERAPEUTICS : Announces Positive Expression Results from the Casimersen..
AQ
03/28SAREPTA THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and ..
AQ
More news
Analyst Recommendations on SAREPTA THERAPEUTICS INC
More recommendations
Sector news : Bio Therapeutic Drugs
04/24S&P 500 closes at record high, even as EPS growth stagnates
RE
04/24EXACT SCIENCES : Older workers helped fuel recent U.S. growth. Can it last?
RE
04/16GILEAD SCIENCES : Insitro to Collaborate on Nonalcoholic Steatohepatitis
DJ
04/15PATRICK THOMAS : Novartis Files Application for Macular Degeneration Treatment
DJ
04/12GILEAD SCIENCES : Novo Nordisk Plan NASH Collaboration
DJ
More sector news : Bio Therapeutic Drugs
Chart SAREPTA THERAPEUTICS INC
Duration : Period :
Sarepta Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAREPTA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 206 $
Spread / Average Target 74%
EPS Revisions
Managers
NameTitle
Douglas S. Ingram President, Chief Executive Officer & Director
M. Kathleen Behrens Chairman
Sandesh Mahatme Executive VP, Chief Financial & Business Officer
Guriqbal S. Basi Chief Scientific Officer
Gilmore O’Neill Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
SAREPTA THERAPEUTICS INC8.27%8 700
GILEAD SCIENCES0.40%80 369
VERTEX PHARMACEUTICALS5.83%44 835
REGENERON PHARMACEUTICALS-7.86%36 949
GENMAB4.82%10 352
BLUEBIRD BIO INC37.22%7 643